Encyclopedia

  • ReviewThe synthesis and luminescent properties of trichromatic iridium complexes based on 2-(4-bromophenyl)-1-hydrogen-benzimidazole
  • Add time:08/22/2019         Source:sciencedirect.com

    The tris-cyclometalated iridium complex Ir(pbi)3 was synthesized regarding 2-(4-bromophenyl)-1-hydrogen-benzimidazole(pbi) as cyclometalated ligand and the heteroleptic iridium complexes (pbi)2Ir(acac) and (pbi)2Ir(phen) were prepared through the ancillary ligands acetylacetone(acac) and 1,10-phenanthroline(phen), respectively. Wherein the complex Ir(pbi)3 gives the maximum emission peak of 436 nm at 365 nm excitation and color coordinate of (0.173, 0.144) as a blue light-emitting. The complexes (pbi)2Ir(acac) and (pbi)2Ir(phen) present the maximum emission wavelength of 536 nm and 616 nm and color coordinates (0.301, 0.591) and (0.630, 0.345) respectively corresponding to the green and red emission. The phosphorescent quantum efficiencies for Ir(pbi)3, (pbi)2Ir(acac) and (pbi)2Ir(phen) in CH2Cl2 are found to be 9.35%, 10.63% and 25.14% respectively, and their quantum efficiencies in powder are found to be 3.27%, 2.74% and 12.21% respectively. Excited-state lifetimes for these iridium complexes are in the microsecond regime(0.13–0.55 us). Such long-lived excited states clearly suggest that the emitting state has triplet character. The cyclic voltammetry curves showed the HOMO energy levels of the trichromatic complexes and the LUMO energy levels were obtained combining the HOMO energy levels and optical band gaps. The optimal molecular structures and the HOMO and LUMO orbital energy levels of the complexes were figured up through DFT theory Gaussian simulation, indicating the basic numerical coincide of theory and experimental values.

    We also recommend Trading Suppliers and Manufacturers of 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid (cas 113808-88-1). Pls Click Website Link as below: cas 113808-88-1 suppliers


    Prev:Short communicationThree pyrazole-3-carboxylic acid complexes as efficient solvent-free heterogeneous catalysts for CC bond formation
    Next: Original article(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1)

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View